Gefitinib

What is Gefitinib?

Gefitinib is a groundbreaking medication primarily used in the treatment of certain types of cancer, specifically advanced or metastatic non-small cell lung cancer (NSCLC). It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs), which are a form of targeted therapy. Unlike traditional chemotherapy that attacks rapidly dividing cells indiscriminately, Gefitinib works by targeting specific molecular pathways involved in cancer cell growth and survival. Marketed under the brand name Iressa, it has revolutionized the approach to lung cancer treatment for eligible patients.

This medication is an EGFR inhibitor, meaning it specifically targets the epidermal growth factor receptor (EGFR). EGFR is a protein found on the surface of many cells, including cancer cells, and plays a crucial role in cell growth, division, and survival. In some cancers, particularly NSCLC, mutations in the EGFR gene can lead to uncontrolled cell growth, making it a key target for therapeutic intervention.

How Does it Work?

The mechanism of action of Gefitinib is highly specific. Cancer cells with certain activating EGFR mutations rely heavily on the signaling pathways initiated by this receptor for their survival and proliferation. Gefitinib works by reversibly binding to the adenosine triphosphate (ATP)-binding site of the EGFR tyrosine kinase domain. By doing so, it inhibits the phosphorylation of EGFR, which is a critical step in the signaling cascade.

When EGFR phosphorylation is blocked, the downstream signaling pathways (such as RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways) are disrupted. This disruption leads to several anti-cancer effects, including:

• Inhibition of cancer cell proliferation and survival.
• Induction of apoptosis (programmed cell death) in cancer cells.
• Inhibition of angiogenesis (formation of new blood vessels that feed tumors).
• Reduction of metastatic potential.

Ultimately, Gefitinib effectively halts the growth and spread of cancer cells that are dependent on the mutated EGFR pathway, offering a more precise and often less toxic treatment option compared to conventional chemotherapy.

Medical Uses

The primary medical use of Gefitinib is for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that harbors activating mutations of the EGFR gene. These mutations are typically identified through specific molecular diagnostic tests performed on tumor tissue or blood samples. The most common activating EGFR mutations that respond to Gefitinib include exon 19 deletions and exon 21 L858R substitution.

Gefitinib is often used as a first-line treatment for these patients, demonstrating superior progression-free survival and improved quality of life compared to standard platinum-based chemotherapy regimens. It can also be considered for patients who have previously received chemotherapy but whose disease has progressed, provided they have the relevant EGFR mutations.

The identification of these specific genetic mutations before starting treatment is crucial, as Gefitinib is only effective in patients whose tumors express these particular EGFR abnormalities. This personalized medicine approach ensures that patients receive the most appropriate and effective therapy for their specific type of cancer.

Dosage

The standard recommended dosage of Gefitinib is 250 mg taken orally once daily. It can be taken with or without food. For patients who have difficulty swallowing, the tablet can be dispersed in half a glass of plain water (non-carbonated). The tablet should not be crushed or chewed, and the dispersion should be drunk immediately once dissolved.

It is crucial to follow the prescribing physician's instructions precisely. If a dose is missed, and the next dose is more than 12 hours away, the patient should take the missed dose. However, if the next dose is due within 12 hours, the missed dose should be skipped, and the regular dosing schedule resumed. Double doses should never be taken to make up for a missed one.

Dose adjustments may be necessary based on the patient's tolerance to side effects. Any changes to the dosage or treatment schedule should only be made under the guidance of a healthcare professional.

Side Effects

While Gefitinib is generally well-tolerated, like all medications, it can cause side effects. These can range from mild to severe, and patients should report any new or worsening symptoms to their doctor.

Common side effects (affecting more than 1 in 10 patients) include:

• Diarrhea (often manageable with anti-diarrheal medication)
• Skin rash (acne-like, often on the face and chest)
• Dry skin, itching
• Nausea and vomiting
• Asthenia (weakness or lack of energy)
• Anorexia (loss of appetite)
• Oral mucositis (sore mouth)
• Elevated liver enzymes (usually asymptomatic and reversible)

Less common but more serious side effects (affecting fewer than 1 in 100 patients) include:

• Interstitial Lung Disease (ILD): A serious lung condition that can be life-threatening. Symptoms include shortness of breath, cough, and fever. Immediate medical attention is required.
• Liver problems: Severe liver injury, though rare.
• Eye disorders: Conjunctivitis, blepharitis, dry eyes.
• Gastrointestinal perforation: Very rare but serious.
• Pancreatitis: Inflammation of the pancreas.
• Hematuria (blood in urine) or proteinuria (protein in urine).

Patients should be monitored regularly for these potential side effects, and prompt management is essential for patient safety and treatment continuation.

Drug Interactions

Gefitinib is metabolized by the cytochrome P450 enzyme system, specifically CYP3A4. Therefore, it can interact with other drugs that affect this enzyme, potentially altering Gefitinib's effectiveness or increasing its toxicity.

• CYP3A4 Inducers: Medications like rifampicin (an antibiotic), phenytoin, carbamazepine, and phenobarbital (anti-seizure medications), and St. John's wort can decrease Gefitinib concentrations in the blood, reducing its efficacy. Co-administration should be avoided if possible.
• CYP3A4 Inhibitors: Drugs such as ketoconazole, itraconazole (antifungals), erythromycin, clarithromycin (antibiotics), and protease inhibitors (for HIV) can increase Gefitinib concentrations, potentially leading to increased side effects. Dose adjustments or careful monitoring may be necessary.
• pH-Altering Drugs: Medications that increase gastric pH, such as antacids, H2-receptor antagonists (e.g., ranitidine), and proton pump inhibitors (e.g., omeprazole), can reduce Gefitinib absorption and bioavailability. It is generally recommended to avoid concomitant use or administer Gefitinib at least 6 hours before or 10 hours after these agents, where possible.
• Warfarin: Co-administration with warfarin may increase INR and bleeding risk. Close monitoring of INR is recommended.

Patients should always inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential drug interactions.

FAQ

Is Gefitinib chemotherapy?

No, Gefitinib is not traditional chemotherapy. It is a targeted therapy, which works by specifically attacking cancer cells that have certain genetic mutations, unlike chemotherapy which generally targets all rapidly dividing cells.

How long do patients typically take Gefitinib?

Patients typically take Gefitinib until there is evidence of disease progression or until they experience unacceptable toxicity (side effects that outweigh the benefits of treatment). The duration of treatment can vary significantly among individuals.

Can Gefitinib cure lung cancer?

While Gefitinib can significantly improve outcomes, prolong progression-free survival, and enhance the quality of life for patients with EGFR-mutated NSCLC, it is generally not considered a cure. It is a highly effective treatment that manages the disease.

What tests are needed before starting Gefitinib?

Before starting Gefitinib, patients must undergo molecular diagnostic testing, usually on a tumor biopsy, to confirm the presence of activating EGFR mutations (e.g., exon 19 deletions or exon 21 L858R substitution). This ensures the patient is likely to benefit from the treatment.

What is the brand name of Gefitinib?

The original brand name for Gefitinib is Iressa.

Products containing Gefitinib are available through trusted online pharmacies. You can browse Gefitinib-based medications at ShipperVIP or Medicenter.

Summary

Gefitinib represents a significant advancement in the treatment of advanced or metastatic non-small cell lung cancer, particularly for patients whose tumors harbor specific activating EGFR mutations. As an EGFR inhibitor and tyrosine kinase inhibitor, it exemplifies the power of targeted therapy in personalized cancer medicine. By selectively blocking crucial signaling pathways, Gefitinib can effectively control tumor growth and improve patient outcomes. While generally well-tolerated, awareness of its potential side effects and drug interactions is vital for safe and effective use. Ongoing research continues to explore its optimal role and combination therapies, reinforcing its importance in the evolving landscape of cancer care.